Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
about
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic TargetingEfficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II studySneaky side effects and ineffectiveness of an immunotherapy with ipilimumab in a case of metastatic melanoma.Ipilimumab in melanoma.Nivolumab in melanoma.Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors.Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'.Trial watch: Immune checkpoint blockers for cancer therapy.Oridonin inhibits migration, invasion, adhesion and TGF-β1-induced epithelial-mesenchymal transition of melanoma cells by inhibiting the activity of PI3K/Akt/GSK-3β signaling pathway.Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management.A Case of Fulminant Type 1 Diabetes Mellitus Accompanied by Positive Conversion of Anti-insulin Antibody after the Administration of Anti-CTLA-4 Antibody Following the Discontinuation of Anti-PD-1 Antibody.Thyrotoxicosis and Adrenocortical Hormone Deficiency During Immune-checkpoint Inhibitor Treatment for Malignant Melanoma.Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.Current status and perspectives in immunotherapy for metastatic melanoma.Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab.Clinical assessment of immune-related adverse events.Anti-PD-1 monotherapy versus anti-PD1 plus anti-CTLA4 in advanced melanoma: how do we decide?Utility of ipilimumab in melanoma patients who progress on anti-PD-1 therapyBullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma
P2860
Q26742012-8413D781-8897-4F26-91CB-F1E9763F429CQ33823259-3EEF45A3-022F-46D3-A979-4ABD95024545Q37158935-66C789EC-0573-436C-AE84-D515894004C0Q38893697-B723CEE1-1C5A-4844-97F5-6B8557415E9AQ38989508-68E959A3-57D1-4253-B1B9-5945B0762C02Q39009781-95E49418-3869-4D21-A288-6B780F8E5465Q40285553-D71D0613-FB93-4532-8300-38BA012E92D5Q47393365-7DB37136-E1E2-489A-8F85-13E371EA2A34Q49334938-4BDD7188-37E6-419E-B7C6-969A80856ABEQ50205173-307DF648-740E-4321-B490-E09B4B69C2D1Q52611551-61F88038-EC5D-4795-A381-46D6309B9901Q52680743-F08DBFD3-93B9-461D-A74E-15972E8DBB57Q52687765-FB3A4DF7-081B-48CE-AB99-AA34C17C22C4Q53415548-80867A4B-1557-4385-BD4D-06611291D859Q54574397-58D0E603-7B5A-4CF2-97D4-18CC7157143BQ55029098-19DA06D4-D937-4785-8F81-04B316DB5550Q55292659-963DD3F4-2984-4715-8387-75FE596ECEBBQ56893675-F51F8394-09E9-4AFF-99C8-AFDDB4A5BA22Q56893686-5EB6EF1A-6AF1-4C83-ADF7-136FFBF0D281Q57298150-9400D570-9538-411C-80A9-63C5D05673FD
P2860
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Efficacy and toxicity of treat ...... after prior anti-PD-1 therapy
@en
type
label
Efficacy and toxicity of treat ...... after prior anti-PD-1 therapy
@en
prefLabel
Efficacy and toxicity of treat ...... after prior anti-PD-1 therapy
@en
P2093
P2860
P50
P356
P1476
Efficacy and toxicity of treat ...... after prior anti-PD-1 therapy
@en
P2093
A Guminski
M Millward
M S Carlino
P Prithviraj
P2860
P2888
P304
P356
10.1038/BJC.2016.107
P407
P577
2016-04-28T00:00:00Z